Safety and immunogenicity of a subunit respiratory syncytial virus vaccine in children 24 to 48 months old

Clicks: 344
ID: 117149
1994
Free PDF
Article Quality & Performance Metrics
Overall Quality Improving Quality
0.0 /100
Combines engagement data with AI-assessed academic quality
AI Quality Assessment
Not analyzed
Abstract
A subunit vaccine for respiratory syncytial virus (RSV) consisting of purified fusion glycoprotein (designated PFP-1) was tested in children 24 to 48 months old. Two doses of 20 micrograms (n = 13) and 50 micrograms (n = 10) were compared with a saline (n = 24) placebo control group. Local and syste …
Reference Key
pr1994thesafety Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Paradiso PR;Hildreth SW;Hogerman DA;Speelman DJ;Lewin EB;Oren J;Smith DH;;
Journal the pediatric infectious disease journal
Year 1994
DOI
DOI not found
URL
http://www.ncbi.nlm.nih.gov/pubmed/7808848
Keywords
National Center for Biotechnology Information NCBI NLM MEDLINE humans pubmed abstract nih national institutes of health national library of medicine female male Child preschool Clinical Trial Randomized Controlled Trial follow-up studies Cohort Studies neutralization tests respiratory syncytial virus infections / prevention & control* enzyme-linked immunosorbent assay viral fusion proteins / immunology* p r paradiso human / immunology* human / isolation & purification respiratory syncytial virus vaccination* pmid:7808848 doi:10.1097/00006454-199409000-00008 s w hildreth d h smith

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.